Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

NCT00295932 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

79

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: bortezomib
DRUG: cyclophosphamide
DRUG: prednisone

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]